Floatz logo

SODIUM ZIRCONIUM CYCLOSILICATE

Abdominal Obesity Metabolic Syndrome

Maastricht University Medical CenterSmall moleculePhase 4 / ApprovedDormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Abdominal Obesity Metabolic Syndrome cohort.

Asset / SponsorPhaseRating
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
University of Sao Paulo
Phase 4BB
Als-L1023
Hanmi Pharmaceutical Company Limited
Phase 3B
Eplerenone
Maastricht University Medical Center
Phase 4B

Same molecule, other indications

SODIUM ZIRCONIUM CYCLOSILICATE is also rated in:

Metabolic SyndromeDormant
B
Indicative ·
57 / 100
View asset →
HypertensionDormant
CCC
Indicative ·
54 / 100
View asset →
Duchenne Muscular DystrophyDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →